tanshinone ii a has been researched along with levodopa in 1 studies
| Studies (tanshinone ii a) | Trials (tanshinone ii a) | Recent Studies (post-2010) (tanshinone ii a) | Studies (levodopa) | Trials (levodopa) | Recent Studies (post-2010) (levodopa) |
|---|---|---|---|---|---|
| 61 | 0 | 41 | 17,774 | 1,900 | 4,946 |
| Protein | Taxonomy | tanshinone ii a (IC50) | levodopa (IC50) |
|---|---|---|---|
| integrase, partial | Human immunodeficiency virus 1 | 0.5939 | |
| lens epithelium-derived growth factor p75 | Homo sapiens (human) | 0.5939 | |
| Epidermal growth factor receptor | Homo sapiens (human) | 2.88 | |
| Tyrosine-protein kinase Lck | Homo sapiens (human) | 3.729 | |
| Tyrosine-protein kinase Fyn | Homo sapiens (human) | 2.146 | |
| Polyunsaturated fatty acid lipoxygenase ALOX15 | Oryctolagus cuniculus (rabbit) | 2.258 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abdeen, S; Chapman, E; Chitre, S; Hoang, QQ; Johnson, SM; Park, Y; Ray, AM; Salim, N; Sivinski, J; Stevens, M; Washburn, A | 1 |
1 other study(ies) available for tanshinone ii a and levodopa
| Article | Year |
|---|---|
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
Topics: Biological Products; Chaperonin 10; Chaperonin 60; Escherichia coli; Humans; Inhibitory Concentration 50; Protein Folding; Rafoxanide; Salicylanilides; Suramin | 2019 |